Antisense & RNAi Therapeutics Market Size, Share, Growth, and Industry Analysis, By Type (RNA Interference, SiRNA, MiRNA, Antisense RNA), By Application (Oncology, Cardiovascular, Renal, Neurodegenerative, Respiratory, Genetic, Infectious Diseases), Regional Insights and Forecast From 2026 To 2035

Detailed TOC of Global Antisense & RNAi Therapeutics Market Research Report 2022

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antisense & RNAi Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2035
1.2.2 RNA Interference
1.2.3 SiRNA
1.2.4 MiRNA
1.2.5 Antisense RNA
1.3 Market by Application
1.3.1 Global Antisense & RNAi Therapeutics Market Share by Application: 2017 VS 2021 VS 2035
1.3.2 Oncology
1.3.3 Cardiovascular
1.3.4 Renal
1.3.5 Neurodegenerative
1.3.6 Respiratory
1.3.7 Genetic
1.3.8 Infectious Diseases
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Antisense & RNAi Therapeutics Market Perspective (2017-2035)
2.2 Antisense & RNAi Therapeutics Growth Trends by Region
2.2.1 Antisense & RNAi Therapeutics Market Size by Region: 2017 VS 2021 VS 2035
2.2.2 Antisense & RNAi Therapeutics Historic Market Size by Region (2017-2022)
2.2.3 Antisense & RNAi Therapeutics Forecasted Market Size by Region (2023-2035)
2.3 Antisense & RNAi Therapeutics Market Dynamics
2.3.1 Antisense & RNAi Therapeutics Industry Trends
2.3.2 Antisense & RNAi Therapeutics Market Drivers
2.3.3 Antisense & RNAi Therapeutics Market Challenges
2.3.4 Antisense & RNAi Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antisense & RNAi Therapeutics Players by Revenue
3.1.1 Global Top Antisense & RNAi Therapeutics Players by Revenue (2017-2022)
3.1.2 Global Antisense & RNAi Therapeutics Revenue Market Share by Players (2017-2022)
3.2 Global Antisense & RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antisense & RNAi Therapeutics Revenue
3.4 Global Antisense & RNAi Therapeutics Market Concentration Ratio
3.4.1 Global Antisense & RNAi Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antisense & RNAi Therapeutics Revenue in 2021
3.5 Antisense & RNAi Therapeutics Key Players Head office and Area Served
3.6 Key Players Antisense & RNAi Therapeutics Product Solution and Service
3.7 Date of Enter into Antisense & RNAi Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antisense & RNAi Therapeutics Breakdown Data by Type
4.1 Global Antisense & RNAi Therapeutics Historic Market Size by Type (2017-2022)
4.2 Global Antisense & RNAi Therapeutics Forecasted Market Size by Type (2023-2035)
5 Antisense & RNAi Therapeutics Breakdown Data by Application
5.1 Global Antisense & RNAi Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Antisense & RNAi Therapeutics Forecasted Market Size by Application (2023-2035)
6 North America
6.1 North America Antisense & RNAi Therapeutics Market Size (2017-2035)
6.2 North America Antisense & RNAi Therapeutics Market Size by Country (2017-2022)
6.3 North America Antisense & RNAi Therapeutics Market Size by Country (2023-2035)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Antisense & RNAi Therapeutics Market Size (2017-2035)
7.2 Europe Antisense & RNAi Therapeutics Market Size by Country (2017-2022)
7.3 Europe Antisense & RNAi Therapeutics Market Size by Country (2023-2035)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antisense & RNAi Therapeutics Market Size (2017-2035)
8.2 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Country (2017-2022)
8.3 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Country (2023-2035)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Antisense & RNAi Therapeutics Market Size (2017-2035)
9.2 Latin America Antisense & RNAi Therapeutics Market Size by Country (2017-2022)
9.3 Latin America Antisense & RNAi Therapeutics Market Size by Country (2023-2035)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antisense & RNAi Therapeutics Market Size (2017-2035)
10.2 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Country (2017-2022)
10.3 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Country (2023-2035)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Glaxo Smith Kline
11.1.1 Glaxo Smith Kline Company Detail
11.1.2 Glaxo Smith Kline Business Overview
11.1.3 Glaxo Smith Kline Antisense & RNAi Therapeutics Introduction
11.1.4 Glaxo Smith Kline Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.1.5 Glaxo Smith Kline Recent Development
11.2 Sanofi Aventis / Genzyme
11.2.1 Sanofi Aventis / Genzyme Company Detail
11.2.2 Sanofi Aventis / Genzyme Business Overview
11.2.3 Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Introduction
11.2.4 Sanofi Aventis / Genzyme Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.2.5 Sanofi Aventis / Genzyme Recent Development
11.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals
11.3.1 Isis Pharmaceuticals/ Ionis Pharmaceuticals Company Detail
11.3.2 Isis Pharmaceuticals/ Ionis Pharmaceuticals Business Overview
11.3.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Introduction
11.3.4 Isis Pharmaceuticals/ Ionis Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.3.5 Isis Pharmaceuticals/ Ionis Pharmaceuticals Recent Development
11.4 Arbutus Biopharma Ltd.
11.4.1 Arbutus Biopharma Ltd. Company Detail
11.4.2 Arbutus Biopharma Ltd. Business Overview
11.4.3 Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Introduction
11.4.4 Arbutus Biopharma Ltd. Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.4.5 Arbutus Biopharma Ltd. Recent Development
11.5 Silence Therapeutics
11.5.1 Silence Therapeutics Company Detail
11.5.2 Silence Therapeutics Business Overview
11.5.3 Silence Therapeutics Antisense & RNAi Therapeutics Introduction
11.5.4 Silence Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.5.5 Silence Therapeutics Recent Development
11.6 Bio-Path Holdings Inc.
11.6.1 Bio-Path Holdings Inc. Company Detail
11.6.2 Bio-Path Holdings Inc. Business Overview
11.6.3 Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Introduction
11.6.4 Bio-Path Holdings Inc. Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.6.5 Bio-Path Holdings Inc. Recent Development
11.7 Calando Pharmaceuticals
11.7.1 Calando Pharmaceuticals Company Detail
11.7.2 Calando Pharmaceuticals Business Overview
11.7.3 Calando Pharmaceuticals Antisense & RNAi Therapeutics Introduction
11.7.4 Calando Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.7.5 Calando Pharmaceuticals Recent Development
11.8 ICo Therapeutics
11.8.1 ICo Therapeutics Company Detail
11.8.2 ICo Therapeutics Business Overview
11.8.3 ICo Therapeutics Antisense & RNAi Therapeutics Introduction
11.8.4 ICo Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.8.5 ICo Therapeutics Recent Development
11.9 Quark Pharmaceuticals
11.9.1 Quark Pharmaceuticals Company Detail
11.9.2 Quark Pharmaceuticals Business Overview
11.9.3 Quark Pharmaceuticals Antisense & RNAi Therapeutics Introduction
11.9.4 Quark Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.9.5 Quark Pharmaceuticals Recent Development
11.10 Rexhan Pharmaceuticals
11.10.1 Rexhan Pharmaceuticals Company Detail
11.10.2 Rexhan Pharmaceuticals Business Overview
11.10.3 Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Introduction
11.10.4 Rexhan Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.10.5 Rexhan Pharmaceuticals Recent Development
11.11 Biomarin/Prosensa
11.11.1 Biomarin/Prosensa Company Detail
11.11.2 Biomarin/Prosensa Business Overview
11.11.3 Biomarin/Prosensa Antisense & RNAi Therapeutics Introduction
11.11.4 Biomarin/Prosensa Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.11.5 Biomarin/Prosensa Recent Development
11.12 Regulus Therapeutics
11.12.1 Regulus Therapeutics Company Detail
11.12.2 Regulus Therapeutics Business Overview
11.12.3 Regulus Therapeutics Antisense & RNAi Therapeutics Introduction
11.12.4 Regulus Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.12.5 Regulus Therapeutics Recent Development
11.13 Rxi Pharmaceuticals
11.13.1 Rxi Pharmaceuticals Company Detail
11.13.2 Rxi Pharmaceuticals Business Overview
11.13.3 Rxi Pharmaceuticals Antisense & RNAi Therapeutics Introduction
11.13.4 Rxi Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.13.5 Rxi Pharmaceuticals Recent Development
11.14 Silenseed
11.14.1 Silenseed Company Detail
11.14.2 Silenseed Business Overview
11.14.3 Silenseed Antisense & RNAi Therapeutics Introduction
11.14.4 Silenseed Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.14.5 Silenseed Recent Development
11.15 Dicerna Pharmaceuticals
11.15.1 Dicerna Pharmaceuticals Company Detail
11.15.2 Dicerna Pharmaceuticals Business Overview
11.15.3 Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Introduction
11.15.4 Dicerna Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.15.5 Dicerna Pharmaceuticals Recent Development
11.16 Sirnaomics Inc.
11.16.1 Sirnaomics Inc. Company Detail
11.16.2 Sirnaomics Inc. Business Overview
11.16.3 Sirnaomics Inc. Antisense & RNAi Therapeutics Introduction
11.16.4 Sirnaomics Inc. Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.16.5 Sirnaomics Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details